Showing 1811-1820 of 3043 results for "".
- General Medicine Update: Daily Aspirin May Not Work Wonders After Allhttps://practicaldermatology.com/news/general-medicine-update-daily-aspirin-may-not-work-wonders-after-all/2457633/It remains unclear whether daily aspirin lowers the risk of a cardiovascular event in individuals at moderate risk of a first heart attack or stroke, according to late-breaking results from the ARRIVE study presented at the European Society of Cardiology (ESC) Congress 2018 a
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://practicaldermatology.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2457649/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument&#
- Experimental Drug May Reverse Hair Loss, Hair Whitening and Skin Inflammationhttps://practicaldermatology.com/news/experimental-drug-may-reverse-hair-loss-hair-whitening-and-skin-inflammation/2457669/An experimental drug can successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol, according to a new Johns Hopkins study in mice. The investigators say the compound halts the production of glycosphingolipi
- Survey: Most Women Think Their Hands Make Them Look Oldhttps://practicaldermatology.com/news/survey-most-women-think-their-hands-make-them-look-old/2457674/Just shy of 80 percent of women ages 40 and older wish they could change the way their hands look, according to Nestlé Skin Health’s 'Face Your Hands' survey. Additionally, 60 percent reported they have actually taken step
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod
- Hair Products for Black Women May Contain Mix of Hazardous Ingredientshttps://practicaldermatology.com/news/hair-products-for-black-women-may-contain-mix-of-hazardous-ingredients/2457790/Black women are potentially exposed to dozens of hazardous chemicals through their hair products, finds a new report in the journal Environmental Research. The study, led by scientists at Silent Spr
- GlobalData: Sun Pharma's Ilumya To Face Strong Competition in the US markethttps://practicaldermatology.com/news/globaldata-sun-pharmas-ilumya-will-face-strong-competition-in-the-us-market/2457816/It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from
- South Beach Symposium to Kick Off March 1https://practicaldermatology.com/news/south-beach-symposium-to-kick-off-march-1/2457895/Now celebrating its 16th year, the 2018 South Beach Symposium (SBS) will feature live demonstration workshops of minimally invasive aesthetic treatments with injectables and devices providing attendees with new skills and techniques th
- Allergan Rolls Out "Not Cool vs. Cool"CoolSculpting Campaign Starring Professional Male Athlete Brand Ambassadorshttps://practicaldermatology.com/news/allergan-rolls-out-not-cool-vs-coolcoolsculpting-campaign-starring-professional-male-athlete-brand-ambassadors/2457905/Allergan’s new "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® stars Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Go
- Desmoplastic Melanoma May Be Highly Responsive to Anti-PD-1/PD-L1 Therapieshttps://practicaldermatology.com/news/desmoplastic-melanoma-may-be-highly-responsive-to-anti-pd-1pd-l1-therapies/2457926/Patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature. Pembrolizumab and niv